JAMA Health Forum最新文献

筛选
英文 中文
Value-Based State-Directed Payments in Medicaid Managed Care. 医疗补助管理医疗中基于价值的国家指导支付。
IF 9.5
JAMA Health Forum Pub Date : 2025-06-07 DOI: 10.1001/jamahealthforum.2025.1666
Max Yates, Jonathan Gonzalez-Smith, Kun Li, Asher Wang, Robert R Saunders
{"title":"Value-Based State-Directed Payments in Medicaid Managed Care.","authors":"Max Yates, Jonathan Gonzalez-Smith, Kun Li, Asher Wang, Robert R Saunders","doi":"10.1001/jamahealthforum.2025.1666","DOIUrl":"10.1001/jamahealthforum.2025.1666","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 6","pages":"e251666"},"PeriodicalIF":9.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Public Health Implications of Legal Challenges to the FDA's Regulation of Laboratory-Developed Tests. 对FDA实验室开发测试法规的法律挑战对公众健康的影响。
IF 9.5
JAMA Health Forum Pub Date : 2025-06-07 DOI: 10.1001/jamahealthforum.2025.2233
Kushal T Kadakia, Joseph S Ross, Reshma Ramachandran
{"title":"Public Health Implications of Legal Challenges to the FDA's Regulation of Laboratory-Developed Tests.","authors":"Kushal T Kadakia, Joseph S Ross, Reshma Ramachandran","doi":"10.1001/jamahealthforum.2025.2233","DOIUrl":"10.1001/jamahealthforum.2025.2233","url":null,"abstract":"<p><strong>Importance: </strong>Laboratory-developed tests (LDTs) refer to in vitro diagnostics developed and used by individual laboratories. LDTs are widely used in modern medicine, with their results informing over 70% of clinical decisions. The US Food and Drug Administration (FDA) has historically claimed regulatory authority over LDTs and, in 2024, finalized new regulations to strengthen oversight of these products. However, the FDA's rulemaking was vacated in the 2025 court case American Clinical Laboratory Association et al v FDA et al, a decision that has carried substantial implications for public health.</p><p><strong>Observations: </strong>The FDA has possessed oversight of in vitro diagnostic tests, including LDTs, since the US Congress passed the Medical Device Amendments Act of 1976. Due to their limited use, the FDA initially exempted LDTs from formal requirements for premarket clinical testing and regulatory review. These regulatory flexibilities enabled substantial innovation in diagnostic technology, enabling the development of LDTs for applications including routine clinical care, complex molecular testing, and rapid response during public health emergencies. However, the exponential growth of LDTs in clinical practice despite little to no clinical evidence of safety and effectiveness has raised public health concerns from the FDA and Congress, with subsequent investigations identifying substantial issues related to test quality and performance. These findings motivated the FDA to issue a new rule expanding its risk-based approach to LDT regulation that was subsequently challenged in the US District Court for the Eastern District of Texas by the American Clinical Laboratory Association and the Association of Molecular Pathology. The court ruled in favor of the plaintiffs and moved to vacate the FDA's LDT rule, asserting that LDTs constituted services, not products, and were therefore beyond the scope of the FDA's medical device authorities. Applying the Supreme Court's recent decision to overturn the Chevron doctrine that deferred to agency interpretation in implementing statute, the court also ruled that the FDA could not regulate LDTs without the express authorization of Congress.</p><p><strong>Conclusions and relevance: </strong>The case of LDTs illustrates the challenges the FDA faces when adapting regulatory frameworks in response to emerging health technologies. The outcomes of recent reforms and litigation carry substantial public health implications for both diagnostic technologies and the FDA's broader regulatory remit.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 6","pages":"e252233"},"PeriodicalIF":9.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Error in Results Section. 结果部分出现错误。
IF 9.5
JAMA Health Forum Pub Date : 2025-06-07 DOI: 10.1001/jamahealthforum.2025.2563
{"title":"Error in Results Section.","authors":"","doi":"10.1001/jamahealthforum.2025.2563","DOIUrl":"10.1001/jamahealthforum.2025.2563","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 6","pages":"e252563"},"PeriodicalIF":9.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cannabis Legalization and Opioid Use Disorder in Veterans Health Administration Patients. 退伍军人健康管理患者的大麻合法化和阿片类药物使用障碍。
IF 9.5
JAMA Health Forum Pub Date : 2025-06-07 DOI: 10.1001/jamahealthforum.2025.1369
Zachary L Mannes, Melanie M Wall, Daniel M Alschuler, Carol A Malte, Mark Olfson, Ofir Livne, David S Fink, Salomeh Keyhani, Katherine M Keyes, Silvia S Martins, Magdalena Cerdá, Dana L Sacco, Sarah Gutkind, Charles C Maynard, Scott Sherman, Andrew J Saxon, Deborah S Hasin
{"title":"Cannabis Legalization and Opioid Use Disorder in Veterans Health Administration Patients.","authors":"Zachary L Mannes, Melanie M Wall, Daniel M Alschuler, Carol A Malte, Mark Olfson, Ofir Livne, David S Fink, Salomeh Keyhani, Katherine M Keyes, Silvia S Martins, Magdalena Cerdá, Dana L Sacco, Sarah Gutkind, Charles C Maynard, Scott Sherman, Andrew J Saxon, Deborah S Hasin","doi":"10.1001/jamahealthforum.2025.1369","DOIUrl":"10.1001/jamahealthforum.2025.1369","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;In the context of the US opioid crisis, factors associated with the prevalence of opioid use disorder (OUD) must be identified to aid prevention and treatment. State medical cannabis laws (MCL) and recreational cannabis laws (RCL) are potential factors associated with OUD prevalence.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To examine changes in OUD prevalence associated with MCL and RCL enactment among veterans treated at the Veterans Health Administration (VHA) and whether associations differed by age or chronic pain.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;Using VHA electronic health records from January 2005 to December 2022, adjusted yearly prevalences of OUD were calculated, controlling for sociodemographic characteristics, receipt of prescription opioids, other substance use disorders, and time-varying state covariates. Staggered-adoption difference-in-difference analyses were used for estimates and 95% CIs for the relationship between MCL and RCL enactment and OUD prevalence. The study included VHA patients aged 18 to 75 years. The data were analyzed in December 2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcome and measures: &lt;/strong&gt;International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) OUD diagnoses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;From 2005 to 2022, most patients were male (86.7.%-95.0%) and non-Hispanic White (70.3%-78.7%); the yearly mean age was 61.9 to 63.6 years (approximately 3.2 to 4.5 million patients per year). During the study period, OUD decreased from 1.12% to 1.06% in states without cannabis laws, increased from 1.13% to 1.19% in states that enacted MCL, and remained stable in states that also enacted RCL. OUD prevalence increased significantly by 0.06% (95% CI, 0.05%-0.06%) following MCL enactment and 0.07% (95% CI, 0.06%-0.08%) after RCL enactment. In patients aged 35 to 64 years and 65 to 75 years, MCL and RCL enactment was associated with increased OUD, with the greatest increase after RCL enactment among older adults (0.12%; 95% CI, 0.11%-0.13%). Patients with chronic pain had even larger increases in OUD following MCL (0.08%; 95% CI, 0.07%-0.09%) and RCL enactment (0.13%; 95% CI, 0.12%-0.15%). Consistent with overall findings, the largest increases in OUD occurred among patients with chronic pain aged 35 to 64 years following the enactment of MCL and RCL (0.09%; 95% CI, 0.07%-0.11%) and adults aged 65 to 75 years following RCL enactment (0.23%; 95% CI, 0.21%-0.25%).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;The results of this cohort study suggest that MCL and RCL enactment was associated with greater OUD prevalence in VHA patients over time, with the greatest increases among middle-aged and older patients and those with chronic pain. The findings did not support state cannabis legalization as a means of reducing the burden of OUD during the o","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 6","pages":"e251369"},"PeriodicalIF":9.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Awareness of and Beliefs About Naloxone Among Adults. 成人对纳洛酮的认知与信念。
IF 9.5
JAMA Health Forum Pub Date : 2025-06-07 DOI: 10.1001/jamahealthforum.2025.1867
S Michaela Rikard, Kunal Doshi, Gery P Guy, Kristine M Schmit
{"title":"Awareness of and Beliefs About Naloxone Among Adults.","authors":"S Michaela Rikard, Kunal Doshi, Gery P Guy, Kristine M Schmit","doi":"10.1001/jamahealthforum.2025.1867","DOIUrl":"10.1001/jamahealthforum.2025.1867","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 6","pages":"e251867"},"PeriodicalIF":9.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Until Women's Health Is Everywhere, Women's Health Is Nowhere. 除非妇女的健康无处不在,否则妇女的健康无处可去。
IF 9.5
JAMA Health Forum Pub Date : 2025-06-07 DOI: 10.1001/jamahealthforum.2025.1226
Andrea G Edlow, Lynn M Yee, Alison G Cahill, Cynthia Gyamfi-Bannerman
{"title":"Until Women's Health Is Everywhere, Women's Health Is Nowhere.","authors":"Andrea G Edlow, Lynn M Yee, Alison G Cahill, Cynthia Gyamfi-Bannerman","doi":"10.1001/jamahealthforum.2025.1226","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.1226","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 6","pages":"e251226"},"PeriodicalIF":9.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mortality Outcomes for Survivors of Cancer With Food Insecurity in the US. 美国食品不安全癌症幸存者的死亡率结果
IF 9.5
JAMA Health Forum Pub Date : 2025-06-07 DOI: 10.1001/jamahealthforum.2025.1381
John C Lin, Jiaxuan Sun, Ruiqi Yan, Lucy S Wang, Anne Marie McCarthy, Guangyu Tong, Jaya Aysola
{"title":"Mortality Outcomes for Survivors of Cancer With Food Insecurity in the US.","authors":"John C Lin, Jiaxuan Sun, Ruiqi Yan, Lucy S Wang, Anne Marie McCarthy, Guangyu Tong, Jaya Aysola","doi":"10.1001/jamahealthforum.2025.1381","DOIUrl":"10.1001/jamahealthforum.2025.1381","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Food insecurity, which is characterized by limited or uncertain access to adequate food, affects approximately 40 million individuals in the US, including many patients with cancer. Understanding the association between food insecurity and cancer mortality is crucial for improving patient outcomes and addressing health disparities.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To investigate the association of food insecurity with cancer-specific and all-cause mortality among US adults with a diagnosis of cancer.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This cohort study used nationally representative data from the 2011 to 2012 National Health Interview Survey that were linked to the National Death Index, with mortality follow-up through December 31, 2019. It included 5603 respondents to the National Health Interview Survey 40 years and older who reported receiving a diagnosis of cancer and responded to food security questions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposure: &lt;/strong&gt;Food insecurity was measured using a validated 10-item National Center for Health Statistics food insecurity scale, categorized as food secure (0-2) or food insecure (3-10) based on US Department of Agriculture guidelines.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary outcomes were cancer-specific mortality (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes: C00-C97) and all-cause mortality. Cox proportional hazards models were used to estimate hazard ratios (HRs) for these outcomes, adjusting for age, sex, race and ethnicity, household income, US region, body mass index, smoking, alcohol use, comorbidities, and survey year.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among the 5603 participants (mean [SD] age, 67.03 [12.03] years; 3298 female individuals [59%]; 320 Hispanic individuals [6%], 22 Native American individuals [0.4%], 136 non-Hispanic Asian individuals [2%], 529 non-Hispanic Black individuals [9%], 4519 non-Hispanic White individuals [81%], and 75 multiracial or multiethnic individuals [1%]), the prevalence of food insecurity was 10.3% among survivors of cancer. Food insecurity was associated with higher all-cause mortality (HR, 1.28; 95% CI, 1.07-1.53) but not cancer-specific mortality after full adjustment. Subgroup analyses indicated that food insecurity was associated with cancer and all-cause mortality for those individuals with household incomes 200% or greater than the federal poverty level (cancer-specific mortality: HR, 1.93; 95% CI, 1.18-3.15; all-cause mortality: HR, 1.89; 95% CI, 1.34-2.68) and those not receiving food assistance (cancer-specific mortality: HR, 1.42; 95% CI, 1.00-2.01; all-cause mortality: HR, 1.42; 95% CI, 1.14-1.76). However, there was no significant association between food insecurity and cancer-specific or all-cause mortality for people with incomes less than 100% of the federal poverty level and households participating in food assistance programs.&lt;/p","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 6","pages":"e251381"},"PeriodicalIF":9.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diverging Mortality Trends by Educational Attainment in the US. 美国受教育程度不同的死亡率趋势。
IF 9.5
JAMA Health Forum Pub Date : 2025-06-07 DOI: 10.1001/jamahealthforum.2025.1647
Eugenio Paglino, Elizabeth Wrigley-Field, Andrew C Stokes
{"title":"Diverging Mortality Trends by Educational Attainment in the US.","authors":"Eugenio Paglino, Elizabeth Wrigley-Field, Andrew C Stokes","doi":"10.1001/jamahealthforum.2025.1647","DOIUrl":"10.1001/jamahealthforum.2025.1647","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 6","pages":"e251647"},"PeriodicalIF":9.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Error in Funding/Support. 资助/支持错误。
IF 9.5
JAMA Health Forum Pub Date : 2025-06-07 DOI: 10.1001/jamahealthforum.2025.2413
{"title":"Error in Funding/Support.","authors":"","doi":"10.1001/jamahealthforum.2025.2413","DOIUrl":"10.1001/jamahealthforum.2025.2413","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 6","pages":"e252413"},"PeriodicalIF":9.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Financial Ties, Market Structure, Commercial Prices, and Medical Director Compensation in Dialysis. 透析行业的金融关系、市场结构、商业价格和医疗主管薪酬。
IF 9.5
JAMA Health Forum Pub Date : 2025-06-07 DOI: 10.1001/jamahealthforum.2025.2659
Xuyang Xia, Wanrong Deng, Paul J Eliason, Riley J League, Ryan C McDevitt, James W Roberts, Heather Wong
{"title":"Financial Ties, Market Structure, Commercial Prices, and Medical Director Compensation in Dialysis.","authors":"Xuyang Xia, Wanrong Deng, Paul J Eliason, Riley J League, Ryan C McDevitt, James W Roberts, Heather Wong","doi":"10.1001/jamahealthforum.2025.2659","DOIUrl":"10.1001/jamahealthforum.2025.2659","url":null,"abstract":"<p><strong>Importance: </strong>Growing consolidation in the dialysis industry has raised concerns about market power and the potential need for antitrust enforcement, but a lack of data previously prevented a systematic analysis of these issues.</p><p><strong>Objective: </strong>To document the consolidation of dialysis facilities through chain ownership and vertical integration between dialysis facilities and physicians, as well as study associations between consolidation and commercial prices for outpatient hemodialysis and medical director compensation.</p><p><strong>Design, setting, and participants: </strong>This economic evaluation combined data from Freedom of Information Act requests, Medicare claims, cost reports, commercial prices, and physician registries to conduct a retrospective study of market structure, compensation, and prices in the dialysis industry from 2005 to 2019. Those evaluated include dialysis facilities in the US, physicians involved with dialysis for patients enrolled in Medicare, and patients with end-stage renal disease enrolled in Medicare or one of the commercial insurers in claims data provided by the Health Care Cost Institute. Data were analyzed from April 2024 to April 2025.</p><p><strong>Exposure: </strong>Chain ownership, physician ownership, and medical directorship of dialysis facilities in the US from 2005 to 2019.</p><p><strong>Main outcomes and measures: </strong>Chain ownership of dialysis facilities, share of population living in markets with different levels of chain ownership, share of facilities with physician owners, levels of medical director compensation, and commercial prices for outpatient hemodialysis in markets with different numbers of chain- and physician-owned facilities.</p><p><strong>Results: </strong>Between 2005 and 2019, the market share of DaVita and Fresenius increased from 59.1% to 77.1%, with 32.5% of the national population living in a hospital service area (HSA) without access to a dialysis facility other than these 2 chains in 2019. The share of facilities with a physician owner increased from 11.4% to 29.1%. Markets with only 1 large chain had $495.08 (95% CI, $371.21-$619.85) higher mean commercial prices for outpatient hemodialysis and $564.56 (95% CI, $429.03-$700.10) higher medical director compensation per patient than markets that did not have large chain facilities.</p><p><strong>Conclusions and relevance: </strong>In this economic evaluation, market concentration in the US dialysis industry increased from 2005 to 2019 and was associated with higher commercial prices for outpatient hemodialysis. Physician ownership of facilities also increased, and medical directors received higher pay in markets where large chains operate.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"6 6","pages":"e252659"},"PeriodicalIF":9.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信